Two biosimilar Forsteo (teriparatide) rivals belonging to Pfenex and Alvogen have been recommended for pan-European marketing authorizations by the European Medicines Agency’s Committee for Medicinal Products for Human Use, at the same time as Accord Healthcare announced it was pulling its application for the osteoporosis treatment over bioequivalence study data concerns.
Applications filed by Theramex Ireland under the Livogiva name and Alvogen’s EuroGenerics Holdings business domiciled in the Netherlands under the...






